{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:13Z","timestamp":1786980853455,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05170-7","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T09:56:07Z","timestamp":1552298167000},"page":"781-788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy"],"prefix":"10.1007","volume":"175","author":[{"given":"Nicholas B.","family":"Figura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria T.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homan","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Evernden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Sahebjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-1529","authenticated-orcid":false,"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"5170_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865\u20132872. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"5170_CR2","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977. \n                    https:\/\/doi.org\/10.1002\/cncr.11436\n                    \n                   doi","journal-title":"Cancer"},{"key":"5170_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","volume":"95","author":"C Bonneau","year":"2018","unstructured":"Bonneau C, Paintaud G, Tredan O, Dubot C, Desvignes C, Dieras V, Taillibert S, Tresca P, Turbiez I, Li J, Passot C, Mefti F, Mouret-Fourme E, Le Rhun E, Gutierrez M (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75\u201384. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.02.032","journal-title":"Eur J Cancer"},{"key":"5170_CR4","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1200\/JCO.2012.44.8894","volume":"34","author":"G Bousquet","year":"2016","unstructured":"Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A (2016) Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol 34:e151\u2013e155. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.44.8894","journal-title":"J Clin Oncol"},{"key":"5170_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.21037\/atm.2018.04.35","volume":"6","author":"EM Brosnan","year":"2018","unstructured":"Brosnan EM, Anders CK (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163. \n                    https:\/\/doi.org\/10.21037\/atm.2018.04.35","journal-title":"Ann Transl Med"},{"key":"5170_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-018-4684-3","volume":"169","author":"NB Figura","year":"2018","unstructured":"Figura NB, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA (2018) Intrathecal trastuzumab in the management of HER2 + breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat 169:391\u2013396. \n                    https:\/\/doi.org\/10.1007\/s10549-018-4684-3","journal-title":"Breast Cancer Res Treat"},{"key":"5170_CR7","doi-asserted-by":"publisher","first-page":"Vi58","DOI":"10.1093\/neuonc\/noy148.234","volume":"20","author":"P Kumthekar","year":"2018","unstructured":"Kumthekar P, Gradishar W, Lin N, Pentsova E, Groves M, Jeyapalan S, Melisko M, Grimm S, Lassman AB, Raizer J (2018) Intrathecal (IT) trastuzumab (T) for the treatment of leptomeningeal metastases (LM) in patients (Pts) with human epidermal growth factor receptor 2-positive (HER2+) cancer: a multicenter phase 1\/2 study. Neuro-oncology 20:Vi58","journal-title":"Neuro-oncology"},{"key":"5170_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Rhun Le","year":"2013","unstructured":"Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, Andre C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neuro-oncol 113:83\u201392. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1092-8","journal-title":"J Neuro-oncol"},{"key":"5170_CR9","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608\u20133617. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.01.175","journal-title":"J Clin Oncol"},{"key":"5170_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","volume":"3","author":"NT Lu","year":"2015","unstructured":"Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL (2015) Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2 + breast cancer patient. J Immunother Cancer 3:41. \n                    https:\/\/doi.org\/10.1186\/s40425-015-0084-y","journal-title":"J Immunother Cancer"},{"key":"5170_CR11","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","volume":"19","author":"O Mir","year":"2008","unstructured":"Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978\u20131980. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn654","journal-title":"Ann Oncol"},{"key":"5170_CR12","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, Lad SP, Fecci PE (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8:73312\u201373328. \n                    https:\/\/doi.org\/10.18632\/oncotarget.20272","journal-title":"Oncotarget"},{"key":"5170_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4143\/crt.2014.234","volume":"48","author":"WY Park","year":"2016","unstructured":"Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC (2016) Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis. Cancer Res Treat 48:843\u2013847. \n                    https:\/\/doi.org\/10.4143\/crt.2014.234","journal-title":"Cancer Res Treat"},{"key":"5170_CR14","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","volume":"18","author":"BC Pestalozzi","year":"2000","unstructured":"Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18:2349\u20132351. \n                    https:\/\/doi.org\/10.1200\/JCO.2000.18.11.2349","journal-title":"J Clin Oncol"},{"key":"5170_CR15","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.18632\/oncotarget.5911","volume":"7","author":"BJ Scott","year":"2016","unstructured":"Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer\u2014a systematic review. Oncotarget 7:3740\u20133747. \n                    https:\/\/doi.org\/10.18632\/oncotarget.5911","journal-title":"Oncotarget"},{"key":"5170_CR16","first-page":"1373","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373\u20131377","journal-title":"Oncol Rep"},{"key":"5170_CR17","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B","volume":"52","author":"Y Tsukada","year":"1983","unstructured":"Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349\u20132354","journal-title":"Cancer"},{"key":"5170_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.3.719","journal-title":"J Clin Oncol"},{"key":"5170_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","volume":"18","author":"I Witzel","year":"2016","unstructured":"Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8. \n                    https:\/\/doi.org\/10.1186\/s13058-015-0665-1","journal-title":"Breast Cancer Res"},{"key":"5170_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M (2013) Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139:13\u201322. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2525-y","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05170-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T20:12:13Z","timestamp":1583784733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05170-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5170"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05170-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"10 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}